Glucophage Xr

Glucophage XR is an extended‑release oral tablet that contains the active ingredient metformin hydrochloride. It is marketed in the European Union as a prescription (Rx) medication for the management of type 2 diabetes mellitus. The formulation provides a controlled release of metformin, allowing once‑daily dosing and helping to maintain steady blood glucose levels. It belongs to the biguanide class of antidiabetic drugs and is widely used in clinical practice.

Glucophage XR is indicated for the oral treatment of type 2 diabetes mellitus, particularly when a stable, long‑acting glucose‑lowering effect is desired.

- Improves glycemic control as part of a comprehensive diabetes management plan. - Can be used alone (monotherapy) or in combination with other antidiabetic agents such as sulfonylureas, DPP‑4 inhibitors, or insulin. - Suitable for patients who have difficulty adhering to multiple daily doses of immediate‑release metformin. - Helps reduce hepatic glucose production and increase peripheral insulin sensitivity. - May be considered when lifestyle modifications (diet, exercise) are insufficient to achieve target HbA1c levels.

The safety profile of Glucophage XR includes a range of adverse effects that vary in frequency and severity.

Common: - Nausea - Diarrhea - Abdominal discomfort - Flatulence - Loss of appetite

Serious: - Lactic acidosis (rare but potentially fatal) - Severe hypoglycemia when combined with insulin or sulfonylureas - Hepatotoxicity - Allergic skin reactions such as rash or Stevens‑Johnson syndrome

Before initiating Glucophage XR, clinicians should evaluate several precautionary factors to minimize risks and ensure appropriate use.

- Assess renal function; avoid use in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²). - Review hepatic status, as liver disease may increase the risk of lactic acidosis. - Monitor for signs of vitamin B12 deficiency during long‑term therapy. - Use with caution in elderly patients due to higher susceptibility to renal dysfunction. - Discontinue before any radiographic studies that use iodinated contrast agents. - Counsel patients on recognizing symptoms of lactic acidosis, such as unexplained fatigue or rapid breathing. - Advise against excessive alcohol consumption, which can potentiate lactic acidosis.

Glucophage XR may interact with other medicines, affecting its efficacy or increasing the likelihood of adverse events.

Avoid: - Concomitant use with other biguanides or high‑dose metformin formulations. - Iodinated contrast media for imaging studies without appropriate renal monitoring. - Certain cationic drugs (e.g., amiloride, procainamide) that can reduce metformin clearance.

Use with caution: - Sulfonylureas or insulin, which may increase risk of hypoglycemia. - Loop diuretics (e.g., furosemide) that may impair renal function. - ACE inhibitors or ARBs, especially in patients with renal insufficiency. - Alcohol, which can predispose to lactic acidosis.